France’s financial prosecutor has reportedly launched an investigation into Sanofi’s “financial communication” surrounding the launch of its biggest-selling drug Dupixent.
Shares in Moderna have been under pressure after the company posted a third-quarter loss of $3.6 billion and a steep fall in COVID-19 vaccine sales, although it still thin
Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growt
Sanofi is following in the footsteps of a number of its peers in pharma with a plan to spin off its consumer health business into a separate company and focus its efforts
Shares in EuroAPI, the active pharmaceutical ingredients (API) business spun out of Sanofi last year, have fallen sharply on the back of a sharp slowdown in sales.
Novartis confirmed this morning that it expects to complete the separation of its generic and biosimilar medicines unit Sandoz into an independent company on or around 4th